SA
Go ProLog In
BVS
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
67
Score
4 Buy (67%)2 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
467%
Hold
233%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$13.00
+21.2%
Consensus
$13.00
+21.2%
Bull
$13.00
+21.2%
12-Month Target Range6 analysts
$13.00$13.00$13.00
Current $10.73Consensus
Current Price
$10.73
Upside to Consensus
$2.27

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+6.69%
EPS+16.41%
FY2028
Rev+6.26%
EPS+18.58%
FY2029
Rev+8.00%
EPS+0.31%

Earnings Surprises

Recent Analyst Actions

Feb 9, 2026Barrington
Bioventus initiated with an Outperform at Barrington
Target:$13.00
+52.8%from $8.51
May 7, 2025Craig-Hallum
Bioventus price target lowered to $15 from $17 at Craig-Hallum
Target:$15.00
+141.9%from $6.20
Oct 1, 2024Canaccord Genuity
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
Target:$12.00
+1.8%from $11.79
Aug 7, 2024Craig-Hallum
Bioventus price target raised to $12 from $9 at Craig-Hallum
Target:$12.00
+45.5%from $8.25
May 7, 2024Canaccord Genuity
Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity
Target:$8.00
+56.3%from $5.12
Mar 13, 2024Craig-Hallum
Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum
Target:$9.00
+70.1%from $5.29
Nov 30, 2022Goldman Sachs
Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5
Target:$2.50
+30.9%from $1.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance